Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Yiweikang Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on addressing significant unmet medical needs in immunology, inflammation, and metabolic diseases. Its lead candidate, EVK-101, is a selective JAK1 inhibitor currently undergoing clinical trials for atopic dermatitis and other inflammatory conditions. Additionally, the company is advancing EVK-201, a URAT1 inhibitor designed for the treatment of gout and hyperuricemia. Yiweikang leverages its internal R&D platform to build a diversified pipeline of high-potential drug candidates.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Yiweikang Pharmaceutical.